

Market Announcement

18 November 2024

Resonance Health Ltd (ASX: RHT) – Trading Halt

Description

The securities of Resonance Health Ltd ('RHT') will be placed in trading halt at the request of RHT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 20 November 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

17 November 2024

Mr. Ben Dawson
Senior Adviser, Listings Compliance
ASX Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000
Australia

By email:

Ben.Dawson@asx.com.au

tradinghaltsperth@asx.com.au

Dear Ben

Request for Trading Halt: Resonance Health Ltd (ASX: RHT) (Company)

We request a trading halt to be applied to our ordinary securities pursuant to ASX Listing Rule 17.1 and set out below details of the request:

1. We would like the trading halt to commence from the commencement of trading on 18 November 2024.
2. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a market sensitive announcement in relation to the execution of a material contract for the provision of services in connection with a clinical trial to be conducted by a major pharmaceutical company (**Announcement**).
3. The trading halt is to last until the earlier of the commencement of normal trading on 19 November 2024 or when the Company releases the Announcement.

We are not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information.

Yours sincerely

A handwritten signature in black ink, appearing to read "Mitchell Wells".

Mitchell Wells

**Non-executive Director & Company Secretary
Resonance Health Ltd**